Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript March 5, 2026 REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.3 EPS, expectations were $-1.01. Operator: Thank you for ...

4D Molecular Therapeutics, Inc. ( FDMT) TD Cowen 46th Annual Health Care Conference March 3, 2026 10:30 AM EST ...

Subretinal Cirovec topline data for wet AMD is projected for Q4 2026, serving as the basis for global regulatory submissions ...

RegenXBio reported that dosing is complete in the AFFINITY pivotal Duchenne trial, with robust enrollment in the confirmatory study and encouraging Phase 1/2 data. At 18 months, treated boys showed a ...

Science has added a whole lot more cash to the bank, bringing in an impressive $230 million in its latest raise. | Science has added a whole lot more cash to the bank, bringing in an impressive $230 ...

This isn’t just a simple cash injection; it is a strategic “hard-coding” of Lumentum into Nvidia’s supply chain. In a ...

Eyepoint Pharma () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update ...

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

Earlier pegcetacoplan treatment preserved twice as much retinal tissue compared to delayed treatment in patients with geographic atrophy (GA) secondary to age-related macular dege ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...